论文部分内容阅读
近期,包括中国在内的九国专家更新简化了肺动脉高压(PAH)的治疗流程。(J Am Coll Cardiol,2013,62:D60)写作组专家指出,自1998年以来,PAH治疗方案变得越来越复杂。至2003年,PAH治疗方案发展至5种药物,分为前列腺素、内皮素受体拮抗剂(ERA)和磷酸二酯酶5抑制剂(PDE-5I)三大类,包括口服、吸入、皮下注射和静脉注射4种给药途径。2008年又增加了4种PAH治疗药物,其中西他生坦最终撤市。
Recently, the update of nine experts including China has simplified the treatment of pulmonary hypertension (PAH). (J Am Coll Cardiol, 2013, 62: D60) Writing group experts point out that PAH treatment has become more complex since 1998. By 2003, PAH treatment regimen developed to five kinds of drugs and divided into three categories: prostaglandin, endothelin receptor antagonist (ERA) and phosphodiesterase 5 inhibitor (PDE-5I), including oral, inhalation, subcutaneous Injection and intravenous injection of four routes of administration. Four more PAH treatments were added in 2008, with sitetan eventually withdrawn.